- Home
- NUE vs ARGX Comparison
NUE vs ARGX Comparison
Compare NUE & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUE
- ARGX
- Stock Information
- Founded
- NUE 1905
- ARGX 2008
- Country
- NUE United States
- ARGX Netherlands
- Employees
- NUE N/A
- ARGX N/A
- Industry
- NUE Steel/Iron Ore
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NUE Industrials
- ARGX Health Care
- Exchange
- NUE Nasdaq
- ARGX Nasdaq
- Market Cap
- NUE 34.5B
- ARGX 35.2B
- IPO Year
- NUE N/A
- ARGX 2017
- Fundamental
- Price
- NUE $149.56
- ARGX $589.51
- Analyst Decision
- NUE Buy
- ARGX Strong Buy
- Analyst Count
- NUE 7
- ARGX 21
- Target Price
- NUE $190.57
- ARGX $619.79
- AVG Volume (30 Days)
- NUE 2.1M
- ARGX 302.1K
- Earning Date
- NUE 10-21-2024
- ARGX 10-31-2024
- Dividend Yield
- NUE 1.45%
- ARGX N/A
- EPS Growth
- NUE N/A
- ARGX N/A
- EPS
- NUE 10.40
- ARGX N/A
- Revenue
- NUE $31,362,946,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- NUE N/A
- ARGX $61.99
- Revenue Next Year
- NUE $1.14
- ARGX $42.48
- P/E Ratio
- NUE $14.26
- ARGX N/A
- Revenue Growth
- NUE N/A
- ARGX 85.56
- 52 Week Low
- NUE $133.42
- ARGX $327.73
- 52 Week High
- NUE $203.00
- ARGX $611.22
- Technical
- Relative Strength Index (RSI)
- NUE 47.17
- ARGX 56.12
- Support Level
- NUE $143.71
- ARGX $558.15
- Resistance Level
- NUE $149.94
- ARGX $592.29
- Average True Range (ATR)
- NUE 4.33
- ARGX 12.42
- MACD
- NUE -0.71
- ARGX -2.11
- Stochastic Oscillator
- NUE 20.49
- ARGX 56.76
About NUE Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products, and raw materials, the steel mills segment derives maximum revenue. The steel mills segment includes carbon and alloy steel in sheet, bars, structural and plate; steel trading businesses; rebar distribution businesses; and Nucor's equity method investments in NuMit and NJSM.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.